Bull
$36.73
Scenario price
$32.980
-0.010 (-0.03%)At close
Celsius Holdings, Inc. is engaged in the development, processing, marketing, sale, and distribution of functional energy drinks to a range of consumers. The Company's flagship asset, CELSIUS, is marketed as a lifestyle and energy drink. This product line comes in two versions: a ready-to-drink form and an on-the-go powder form. It also offers a new CELSIUS Essentials line, available in 16-ounce cans and a Hydration line of zero-sugar powders that are infused with electrolytes and are available in a variety of fruit-forward flavors. Celsius products are offered in retail channels across the United States, including conventional grocery, natural, convenience, fitness, mass market, vitamin specialty and e-commerce platforms. Its product's formulation includes ingredients and supplements such as green tea (EGCG), ginger (from the root), calcium, chromium, B vitamins and vitamin C. The Company's product portfolio also includes the health and wellness brand Alani Nu.
Celsius Holdings Inc is currently a hold due to mixed signals in its performance and analyst outlook. The current price is $32.98, and while Goldman Sachs has a bullish target of $45, Deutsche Bank has downgraded it to Hold with a target of $35, reflecting concerns about the company's recent earnings miss and delayed recovery expectations. The RSI is at 54.103, indicating a neutral momentum, and the stock has seen a significant year-to-date decline of 30.93%. The main risk is the recent downgrade from Deutsche Bank, which suggests that the stock may not recover in the near term, while the potential upside remains limited until the company shows clearer signs of recovery.
Deutsche Bank
$35
2026-08-27
Deutsche Bank
2026-08-27
Price Target
$35
Goldman Sachs
$45
2026-08-10
Goldman Sachs
2026-08-10
Price Target
$45
Stephens
$50
2026-08-10
Stephens
2026-08-10
Price Target
$50
Morgan Stanley
$42
2026-08-07
Morgan Stanley
2026-08-07
Price Target
$42
Needham
$35
2026-08-07
Needham
2026-08-07
Price Target
$35
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Deutsche Bank Downgrades Celsius to Hold Amid Weak Q2 Results

Chewy and Celsius: Potential Double-Bagger Stocks

Nvidia Surges 9% After Q2 Earnings Beat Expectations

Tech Stocks Surge as Nvidia Leads Market Rally

Latest Rating Changes on Wall Street
Celsius Holdings, Inc. is engaged in the development, processing, marketing, sale, and distribution of functional energy drinks to a range of consumers. The Company's flagship asset, CELSIUS, is marketed as a lifestyle and energy drink. This product line comes in two versions: a ready-to-drink form and an on-the-go powder form. It also offers a new CELSIUS Essentials line, available in 16-ounce cans and a Hydration line of zero-sugar powders that are infused with electrolytes and are available in a variety of fruit-forward flavors. Celsius products are offered in retail channels across the United States, including conventional grocery, natural, convenience, fitness, mass market, vitamin specialty and e-commerce platforms. Its product's formulation includes ingredients and supplements such as green tea (EGCG), ginger (from the root), calcium, chromium, B vitamins and vitamin C. The Company's product portfolio also includes the health and wellness brand Alani Nu. It operates in the Consumer Non-Cyclicals sector (BOTTLED & CANNED SOFT DRINKS & CARBONATED WATERS industry).
Celsius Holdings Inc is currently a hold due to mixed signals in its performance and analyst outlook. The current price is $32.98, and while Goldman Sachs has a bullish target of $45, Deutsche Bank has downgraded it to Hold with a target of $35, reflecting concerns about the company's recent earnings miss and delayed recovery expectations. The RSI is at 54.103, indicating a neutral momentum, and the stock has seen a significant year-to-date decline of 30.93%. The main risk is the recent downgrade from Deutsche Bank, which suggests that the stock may not recover in the near term, while the potential upside remains limited until the company shows clearer signs of recovery.
1 analysts cover CELH: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 62.85.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.